Thanks to Proven Connects investor partnership with UKRI we were able to be the lead the latest investment round Nanovery. Nanovery have successfully completed funding raise including co-investment from the Northstar Ventures. The £1.85m raise included £750K non-diluted grant funding from Innovatge UK. This funding not only accelerates the company’s progress it also helps to de-risk investments and encourage greater private investment.

Nanovery are developing a technology that will results in patients having a blood test that will provide:

• An earlier and more accurate diagnosis  of prostate cancer reducing the need for unnecessary biopsies
• Support the development and deployment of precision medicine and enable clinicians to better predict the right treatment for the right patient at the right time
• Enable better monitoring of disease progression and so reassure patients who are placed on active surveillance

If successful Nanovery’s technology hopes to not only remove the uncertainty around a prostate cancer diagnosis, in terms of the aggressive nature of a man’s disease. It will also reduce over treatment with the sometimes debilitating and life changing side effects.

Nanovery secures over £1.85 million for cancer diagnostic solution - Prostate Cancer Research (prostate-cancer-research.org.uk)

“I was diagnosed with cancer and after treatment (which was quite difficult) I didn't realise how many questions or experiences I wished I had known about. “(Ray)

If successful Nanovery’s technology will enable men like Ray to receive a diagnosis which tells them how aggressive their cancer is likely to be and recommend the best course of treatment.